Subtype
Large Intestinal Neoplasm
CI-CAN-00001062Explore in graph →
Non-malignant1,847 active trials21 approved drugs383 evidence items
- NCIt
- C215201
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001062Explore in graph →
Clinical trials
8,849 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06162650 | Total Neoadjuvant Therapy in Rectal Cancer | recruiting | Phase 2 | 42 | National Cheng-Kung University HospitalOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07506109 | A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer | recruiting | Phase 2 | 49 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 7, 2026 |
| clinicaltrials |
| NCT06281405 | CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer(TORCH-iTNT) | recruiting | Phase 2 | 192 | Fudan UniversityOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06553885 | Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC | recruiting | Phase 2 | 40 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07033026 | An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia. | recruiting | Phase 2 | 136 | NGM Biopharmaceuticals, IncINDUSTRY | 4 | Apr 1, 2026 | clinicaltrials |
| NCT07505472 | Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria(STARS-RC10) | recruiting | Phase 2 / Phase 3 | 212 | The First Hospital of Jilin UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06634875 | Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS) | recruiting | Phase 2 | 20 | Buzzard PharmaceuticalsINDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06395519 | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies(ERADIC8) | recruiting | Phase 1 / Phase 2 | 120 | 858 Therapeutics, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06850103 | SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases | recruiting | Phase 2 | 51 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05179889 | Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer | recruiting | Phase 2 / Phase 3 | 308 | Chungnam National University HospitalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05806931 | Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer(SCOTI) | recruiting | Phase 2 | 50 | Rutgers, The State University of New JerseyOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06244771 | A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors(PROSPER) | recruiting | Phase 1 / Phase 2 | 403 | Frontier Medicines CorporationINDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT07478731 | Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer(MA-CRC-II-018) | recruiting | Phase 2 | 48 | Hong QiuOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07468630 | Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma(TRIUNITE-08) | recruiting | Phase 2 | 106 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07463599 | Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma | recruiting | Phase 1 / Phase 2 | 126 | HonorHealth Research InstituteOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT07458529 | Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer(NCRIT-PM9) | recruiting | Phase 2 | 50 | Seventh Medical Center of PLA General HospitalOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07462650 | Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 48 | Beijing BiotechINDUSTRY | 1 | Mar 10, 2026 | clinicaltrials |
| NCT07202364 | A Study of YL202 in Patients With Advanced Solid Tumors | recruiting | Phase 2 | 100 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT06895031 | Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS(STAR) | recruiting | Phase 2 | 210 | Guangzhou JOYO Pharma Co., LtdINDUSTRY | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07432399 | Effect of Perioperative Lidocaine or High-Dose Dexamethasone on Immune Response in Colon Cancer Surgery (PILDI Study)(PILDI) | recruiting | Phase 2 | 100 | Institute of Oncology LjubljanaOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05672108 | Phase II Trial of Lung Chemoemobolization | recruiting | Phase 2 | 30 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05731726 | Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer | recruiting | Phase 2 | 50 | Zhejiang UniversityOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06528990 | Telehealth Intervention for Ostomy Self-Management | recruiting | Phase 2 | 150 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07314294 | Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients | recruiting | Phase 2 | 54 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07447050 | Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial | recruiting | Phase 2 | 24 | University of California, IrvineOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07433283 | Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 54 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07433673 | Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)(GAP Cemi) | recruiting | Phase 2 | 20 | Columbia UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT07281716 | Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC | recruiting | Phase 1 / Phase 2 | 24 | Dan FengOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT06130280 | A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer | recruiting | Phase 2 | 32 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07030257 | Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 150 | Tasca TherapeuticsINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors(SELECT-CAR-NK) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors(EBNK-ST-001) | recruiting | Phase 1 / Phase 2 | 83 | Essen BiotechOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07337876 | Organ Preservation in Rectal Cancer by Dose Escalated MR Guided Adaptive Radiotherapy(MARS) | recruiting | Phase 2 | 100 | University Hospital TuebingenOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07407465 | Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.(CHIMERA) | recruiting | Phase 2 | 42 | Gruppo Oncologico del Nord-OvestOTHER | 4 | Feb 17, 2026 | clinicaltrials |
| NCT06830239 | Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Cancer(Superhero) | recruiting | Phase 2 | 10 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03516708 | Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer | recruiting | Phase 1 / Phase 2 | 49 | Washington University School of MedicineOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06558773 | GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC. | recruiting | Phase 2 | 120 | Chinese PLA General HospitalOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04930432 | Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors | recruiting | Phase 1 / Phase 2 | 400 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07398326 | Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer | recruiting | Phase 2 | 37 | Shanghai Changzheng HospitalOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07391618 | Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU | recruiting | Phase 2 | 583 | Chinese PLA General HospitalOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT06923787 | Effect of Perioperative Intravenous Infusion of Lidocaine on the Postoperative Course and the Immune Response in Patients Undergoing Surgery for Colon Cancer - the PILDI Study(PILDI) | recruiting | Phase 2 | 100 | Institute of Oncology LjubljanaOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06055439 | A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy | recruiting | Phase 1 / Phase 2 | 135 | Chimeric TherapeuticsINDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07151040 | Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors(ODIN) | recruiting | Phase 1 / Phase 2 | 43 | One-carbon Therapeutics ABINDUSTRY | 3 | Jan 28, 2026 | clinicaltrials |
| NCT07371273 | Comparative Study on the Short- and Long-term Efficacy of Q-ISR, Traditional Sub-ISR, and t-ISR | recruiting | Phase 2 | 100 | Fudan UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05954429 | A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study | recruiting | Phase 2 | 50 | Fudan UniversityOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03539822 | Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies(CAMILLA) | recruiting | Phase 1 / Phase 2 | 117 | Anwaar SaeedOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT02584244 | Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers | recruiting | Phase 1 / Phase 2 | 66 | Lumicell, Inc.INDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07347951 | A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer | recruiting | Phase 2 | 30 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06864013 | SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer | recruiting | Phase 2 | 116 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06312982 | A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer | recruiting | Phase 2 / Phase 3 | 375 | Beijing Friendship HospitalOTHER | 1 | Jan 13, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 8, 2026source: clinicaltrials